Testing a three-drug combo for newly diagnosed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with acute myeloid leukemia (AML) and healthy enough to receive strong chemotherapy.
- Your age must be between 18 and 59 years old.
- You should be able to care for yourself but may need some help with daily activities (ECOG score 2 or 3).
- You cannot have serious heart, lung, liver, or kidney problems that are not well controlled.
- You must not have been treated with venetoclax or azacitidine before.
- You cannot have other active cancers, uncontrolled infections, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.